{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:28:23Z","timestamp":1786609703260,"version":"build-2736575974"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiretroviral therapy (ART) that achieves virologic suppression using fewer antiretroviral agents is an optimized approach to HIV-1 treatment initiation. VOGUE is the first randomized, head-to-head study comparing the 2-drug regimen dolutegravir\/lamivudine (DTG\/3TC) with the 3-drug regimen bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) as initial ART, including among individuals with high viral loads (VLs) and\/or low CD4+ cell counts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This phase 3b, randomized (1:1), open-label, noninferiority study compared DTG\/3TC versus BIC\/FTC\/TAF as first-line ART in adults with HIV-1. Participants were enrolled without baseline VL or CD4+ cell count restrictions and initiated treatment before availability of resistance testing results. The primary endpoint was the proportion of participants with HIV-1 RNA &amp;lt;50\u2005copies\/mL at week 48 (Snapshot; \u221210% noninferiority margin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 509 randomized participants (DTG\/3TC, n = 254; BIC\/FTC\/TAF, n = 255), 47% had baseline VL \u2265100 000\u2005copies\/mL and 16% had CD4+ cell count &amp;lt;200\u2005cells\/mm3. At week 48, DTG\/3TC demonstrated noninferior efficacy to BIC\/FTC\/TAF, with HIV-1 RNA &amp;lt;50\u2005copies\/mL achieved in 89% and 92% of participants, respectively (adjusted difference, \u22123% [95% CI, \u22128%, 2%]). Median time to virologic suppression was rapid (4.1 weeks) in both groups. Confirmed virologic withdrawals were similar between groups (n = 7 each), with no treatment-emergent resistance identified. Safety outcomes were comparable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dolutegravir\/Lamivudine demonstrated noninferior efficacy to BIC\/FTC\/TAF as initial ART, with no treatment-emergent resistance through week 48. These findings establish DTG\/3TC as an effective and simplified initial ART regimen across a broad clinical spectrum.<\/jats:p>\n                    <jats:p>Clinical trial registration: \u00a0ClinicalTrials.gov identification number, NCT05979311; URL, https:\/\/clinicaltrials.gov\/study\/NCT05979311<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag471","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:55:41Z","timestamp":1785236141000},"source":"Crossref","is-referenced-by-count":0,"title":["VOGUE: Noninferior Efficacy of Dolutegravir\/Lamivudine Versus Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"first","affiliation":[{"name":"INSERM UMR 1137 IAME, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]},{"name":"Service des Maladies Infectieuses, Assistance Publique - H\u00f4pitaux de Paris Nord, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-8812","authenticated-orcid":false,"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[{"name":"Imas12, UCM, Hospital Universitario 12 de Octubre , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo D","family":"Lopardo","sequence":"additional","affiliation":[{"name":"Fundacion Centro de Estudios Infectologicos , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-1406","authenticated-orcid":false,"given":"Anita","family":"Olczak","sequence":"additional","affiliation":[{"name":"Nicolaus Copernicus University Ludwik Rydygier Collegium Department of Infectious Diseases and Hepatology, , Bydgoszcz ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-6668","authenticated-orcid":false,"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-6230","authenticated-orcid":false,"given":"Charlotte","family":"Martin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Saint-Pierre Department of Infectious Diseases, , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Paredes Ceballos","sequence":"additional","affiliation":[{"name":"Unidad de Atenci\u00f3n M\u00e9dica e Investigaci\u00f3n en Salud , M\u00e9rida, Yucat\u00e1n ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Stocker","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St Joseph Hospital , Berlin-Tempelhof, Berlin ,","place":["Germany"]},{"name":"EPIMED GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5786-3809","authenticated-orcid":false,"given":"Maria Josefina","family":"Mendez Vazquez","sequence":"additional","affiliation":[{"name":"Porto University Hospital Centre Infectious Diseases Service, , Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-9984","authenticated-orcid":false,"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Metallidis","sequence":"additional","affiliation":[{"name":"AHEPA Hospital, Aristotle University of Thessaloniki , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-236X","authenticated-orcid":false,"given":"Daniel","family":"Elbirt","sequence":"additional","affiliation":[{"name":"Allergy, Immunology and HIV Unit, Kaplan Medical Center , Rehovot ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3070-1281","authenticated-orcid":false,"given":"Gary","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Department of HIV\/GUM, Chelsea and Westminster Hospital NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio","family":"Mateo Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Consorcio Hospital General Universitario de Valencia Infectious Diseases Department, , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Mohammed","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Wang","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-4406","authenticated-orcid":false,"given":"Richard","family":"Grove","sequence":"additional","affiliation":[{"name":"GSK , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"Jewell","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Sutton","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-9883","authenticated-orcid":false,"given":"Emilie","family":"Elliot","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Moodley","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Borsi","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-367X","authenticated-orcid":false,"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kisare","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4344-2822","authenticated-orcid":false,"given":"Piotr","family":"Budnik","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the VOGUE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo D","family":"Lopardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo D","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"van Frankenhuijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cazanave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Godinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Makinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Pourcher-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keikawus","family":"Arast\u00e9h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes R","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Metallidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Psichogiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Elbirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eynat","family":"Kedem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzchak","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando Paredes","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Jablonowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Olczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Szetela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Josefina Mendez","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Remedios Alem\u00e1n","family":"Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Bailon","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Garc\u00eda","family":"Deltoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gonzalez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Mallolas","family":"Masferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Olalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchor Riera","family":"Jaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Sorn\u00ed","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Benjamin","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Stoeckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026081303413387800_ofag471-B1","author":"World Health Organization"},{"key":"2026081303413387800_ofag471-B2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"2026081303413387800_ofag471-B3","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2026081303413387800_ofag471-B4","author":"European AIDS Clinical Society"},{"key":"2026081303413387800_ofag471-B5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2026081303413387800_ofag471-B6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2026081303413387800_ofag471-B7","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2026081303413387800_ofag471-B8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch?","volume":"20 Suppl 4","author":"Moreno","year":"2019","journal-title":"HIV Med"},{"key":"2026081303413387800_ofag471-B9","volume-title":"Juluca [prescribing information]","year":"2025"},{"key":"2026081303413387800_ofag471-B10","volume-title":"Dovato [prescribing information]","year":"2025"},{"key":"2026081303413387800_ofag471-B11","volume-title":"Cabenuva [prescribing information]","year":"2025"},{"key":"2026081303413387800_ofag471-B12","volume-title":"Idvynso [prescribing information]","year":"2026"},{"key":"2026081303413387800_ofag471-B13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(26)00307-7","article-title":"Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial","volume":"407","author":"Orkin","year":"2026","journal-title":"Lancet"},{"key":"2026081303413387800_ofag471-B14","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S2352-3018(26)00078-0","article-title":"Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"13","author":"Meissner","year":"2026","journal-title":"Lancet HIV"},{"key":"2026081303413387800_ofag471-B15","author":"Treatment Action Group"},{"key":"2026081303413387800_ofag471-B16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081303413387800_ofag471-B17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2026081303413387800_ofag471-B18","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2352-3018(24)00294-7","article-title":"Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial","volume":"12","author":"Cordova","year":"2025","journal-title":"Lancet HIV"},{"key":"2026081303413387800_ofag471-B19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciaf415","article-title":"Efficacy and safety of dual therapy with dolutegravir\/lamivudine in treatment-naive persons with CD4 counts &lt;200\/mm3: 48-week results of the DOLCE study","volume":"82","author":"Figueroa","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B20","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B23","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2352-3018(25)00105-5","article-title":"Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial","volume":"12","author":"Ryan","year":"2025","journal-title":"Lancet HIV"},{"key":"2026081303413387800_ofag471-B24","doi-asserted-by":"crossref","first-page":"ofae560","DOI":"10.1093\/ofid\/ofae560","article-title":"Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study","volume":"11","author":"Rolle","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026081303413387800_ofag471-B25","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/infdis\/jiae405","article-title":"In-depth analysis of the HIV reservoir confirms effectiveness and safety of dolutegravir\/lamivudine in a phase 4 randomized controlled switch trial (RUMBA)","volume":"231","author":"De Scheerder","year":"2025","journal-title":"J Infect Dis"},{"key":"2026081303413387800_ofag471-B26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40121-024-01103-0","article-title":"Real-world effectiveness and tolerability of dolutegravir and lamivudine 2-drug regimen in people living with HIV: systematic literature review and meta-analysis","volume":"14","author":"Fraysse","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026081303413387800_ofag471-B27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-024-00961-y","article-title":"Two-drug regimens dolutegravir\/lamivudine and dolutegravir\/rilpivirine are effective with few discontinuations in US real-world settings: results from the TANDEM study","volume":"13","author":"Schneider","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026081303413387800_ofag471-B28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40121-024-00950-1","article-title":"Real-world effectiveness of dolutegravir\/lamivudine in people with HIV-1 in test-and-treat settings or with high baseline viral loads: TANDEM study subgroup analyses","volume":"13","author":"Benson","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026081303413387800_ofag471-B29","doi-asserted-by":"crossref","first-page":"ofaf695.578","DOI":"10.1093\/ofid\/ofaf695.578","article-title":"Real-world effectiveness and safety outcomes in people with HIV-1 switching to dolutegravir + lamivudine (DTG + 3TC) with unknown prior genotype: a systematic literature review and meta-analysis [abstract]","volume":"13","author":"Boulos","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"2026081303413387800_ofag471-B30","doi-asserted-by":"crossref","first-page":"ofaf626","DOI":"10.1093\/ofid\/ofaf626","article-title":"Two or three? Clinical and proteomic perspectives on dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide as initial HIV treatment","volume":"12","author":"D\u00edaz-Garc\u00eda","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026081303413387800_ofag471-B31","first-page":"S1808","article-title":"Cost effectiveness of conversion from tenofovir alafenamide (TAF)-based regimen to a two drug regimen program in correctional facilities [abstract]","volume":"82","author":"Walker","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"2026081303413387800_ofag471-B32","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/QAD.0000000000004438","article-title":"Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens","volume":"40","author":"Marcelin","year":"2026","journal-title":"AIDS"},{"key":"2026081303413387800_ofag471-B33","first-page":"535","article-title":"Dolutegravir\/lamivudine in people with HIV with and without prior virologic failure in Thailand [abstract]","volume":"34","author":"Avihingsanon","year":"2026","journal-title":"Top Antivir Med"},{"key":"2026081303413387800_ofag471-B34","first-page":"101835","article-title":"Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir\/emtricitabine\/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China","volume":"68","author":"Wu","year":"2026","journal-title":"Lancet Reg Health West Pac"},{"key":"2026081303413387800_ofag471-B35","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"AIDS"},{"key":"2026081303413387800_ofag471-B36","doi-asserted-by":"crossref","first-page":"ofad101","DOI":"10.1093\/ofid\/ofad101","article-title":"Sustained virologic suppression with dolutegravir\/lamivudine in a test-and-treat setting through 48 weeks","volume":"10","author":"Rolle","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026081303413387800_ofag471-B37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciad219","article-title":"Plasma human immunodeficiency virus 1 RNA and CD4+ T-cell counts are determinants of virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND cohort study","volume":"77","author":"\u00c1lvarez","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/cid\/ciae548","article-title":"Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation","volume":"80","author":"de Waal","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B39","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2352-3018(19)30236-X","article-title":"Optimising treatment in the test-and-treat strategy: what are we waiting for?","volume":"6","author":"Phanuphak","year":"2019","journal-title":"Lancet HIV"},{"key":"2026081303413387800_ofag471-B40","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"key":"2026081303413387800_ofag471-B41","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciag435","article-title":"Impact of HIV-1 RNA assay selection on low-level viremia and clinical trial endpoint interpretations","author":"Geretti","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1740774510396933","article-title":"Bayesian models for subgroup analysis in clinical trials","volume":"8","author":"Jones","year":"2011","journal-title":"Clin Trials"},{"key":"2026081303413387800_ofag471-B43","first-page":"536","article-title":"Meta-analysis of DTG\/3TC vs DTG 3DRs in ART-naive people with high baseline viral loads and low CD4+ [abstract]","volume":"34","author":"Cahn","year":"2026","journal-title":"Top Antivir Med"},{"key":"2026081303413387800_ofag471-B44","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"de Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B45","author":"World Health Organization"},{"key":"2026081303413387800_ofag471-B46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Polaris Observatory Collaborators","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026081303413387800_ofag471-B47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/hiv.70237","article-title":"Efficacy of dolutegravir\/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: insights from phase 3\/3b study results","volume":"27","author":"Fox","year":"2026","journal-title":"HIV Med"},{"key":"2026081303413387800_ofag471-B48","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026081303413387800_ofag471-B49","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciad177","article-title":"Contribution of low CD4 cell counts and high human immunodeficiency virus (HIV) viral load to the efficacy of preferred first-line antiretroviral regimens for treating HIV infection: a systematic review and meta-analysis","volume":"76","author":"Perez-Molina","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026081303413387800_ofag471-B50","doi-asserted-by":"crossref","first-page":"e00292-18","DOI":"10.1128\/JCM.00292-18","article-title":"Multicenter evaluation of two next-generation HIV-1 quantitation assays, Aptima Quant Dx and cobas 6800, in comparison to the RealTime HIV-1 reference assay","volume":"56","author":"Wiesmann","year":"2018","journal-title":"J Clin Microbiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag471\/70252090\/ofag471.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag471\/70252090\/ofag471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag471\/70252090\/ofag471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:41:44Z","timestamp":1786606904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag471\/8743966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag471","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,28]]},"article-number":"ofag471"}}